CRA consultants analyzed market power and alleged anticompetitive conduct for a CNS therapy. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing. Also considered were effects on demand resulting from the change in the form of competition upon the launch of generic products.
Trends in competition in the United States: what does the evidence show?
Has the United States economy become less competitive in recent decades? One might think so based on a body of research that has rapidly become influential for...